InVivoMAb Anti-Human TNFSF9/4-1BBL Antibody (Iv0139)

Catalog No.

VHE32301

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

TNFSF9, 4-1BBL, Tumor necrosis factor ligand superfamily member 9, 4-1BB ligand

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P41273

Applications

ELISA, FCM, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0139

4-1BB stimulation with concomitant inactivation of adenosine A2B receptors enhances CD8+ T cell antitumor response., PMID:40178905

SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137., PMID:39401967

TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab., PMID:39000552

HBV infection effects prognosis and activates the immune response in intrahepatic cholangiocarcinoma., PMID:38206204

Comparative evaluation of antitumor effects of TNF superfamily costimulatory ligands delivered by mesenchymal stem cells., PMID:37995568

Seven chromatin regulators as immune cell infiltration characteristics, potential diagnostic biomarkers and drugs prediction in hepatocellular carcinoma., PMID:37903974

MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway., PMID:37717672

Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents., PMID:37310433

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade., PMID:34290245

The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity., PMID:33362756

An engineered 4-1BBL fusion protein with "activity on demand"., PMID:33239441

A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target., PMID:32015231

CD137-CD137L Signaling Affects Angiogenesis by Mediating Phenotypic Conversion of Macrophages., PMID:31651672

Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody., PMID:31307539

CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15- and IL-21-Driven NK Cell Proliferation., PMID:31201235

Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model., PMID:31194697

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy., PMID:30635578

Contribution of CD137L to Sensory Hypersensitivity in a Murine Model of Neuropathic Pain., PMID:30417077

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer., PMID:30321186

Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody., PMID:28789924

CD137-CD137L interaction modulates neointima formation and the phenotype transformation of vascular smooth muscle cells via NFATc1 signaling., PMID:28770466

Immunological low-dose radiation modulates the pediatric medulloblastoma antigens and enhances antibody-dependent cellular cytotoxicity., PMID:27942918

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody., PMID:27756788

Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling-Project HOPE., PMID:27544999

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer., PMID:27496866

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity., PMID:26106583

Abundance and specificity of influenza reactive circulating memory follicular helper and non-follicular helper CD4 T cells in healthy adults., PMID:26094691

Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapy., PMID:25482887

Expression of B-cell-associated genes in peripheral blood mononuclear cells of patients with symptomatic pulmonary embolism., PMID:25411767

In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion., PMID:23443137

Reverse signaling through the co-stimulatory ligand, CD137L, as a critical mediator of sterile inflammation., PMID:22526397

Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells., PMID:22037570

Ex vivo TCR-induced leukocyte gene expression of inflammatory mediators is increased in type 1 diabetic patients but not in overweight children., PMID:19943328

CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation., PMID:19167994

Ex vivo simulation of IgG Fc and T-cell receptor functions: an application to inflammatory bowel disease., PMID:18340639

Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro., PMID:17675273

Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors., PMID:17460060

Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis., PMID:16970683

Gene therapy using adenoviral vector encoding 4-1BBIg gene significantly prolonged murine cardiac allograft survival., PMID:16860710

Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies., PMID:16708388

4-1BB costimulation enhances HSV-1-specific CD8+ T cell responses by the induction of CD11c+CD8+ T cells., PMID:16524567

A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN)-beta production., PMID:16480981

Immunotherapy targeting 4-1BB and its ligand., PMID:16443548

Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro., PMID:16212924

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease., PMID:16026855

The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma., PMID:15973445

Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes., PMID:15699116

[The role of costimulatory molecule 4-1BB and CD28 in activating of various T cell subsets from human peripheral blood]., PMID:15367340

CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses., PMID:15356173

Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival., PMID:15349720

Document Download

InVivoMAb Anti-Human TNFSF9/4-1BBL Antibody (Iv0139).pdf